Literature DB >> 26109475

Treatment of EBV-associated nodular sclerosing Hodgkin lymphoma in a patient with ataxia telangiectasia with brentuximab vedotin and reduced COPP plus rituximab.

Michael T Meister1, Sandra Voss1, Dirk Schwabe1.   

Abstract

Patients with ataxia telangiectasia (AT) with malignancies face poor prognosis due to increased treatment-related toxicity. Here, we report a 14-year-old male with AT and Hodgkin lymphoma (HL) who received brentuximab vedotin and reduced COPP plus rituximab courses. This treatment resulted in complete remission and showed no severe toxicity.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  Hodgkin lymphoma; ataxia telangiectasia; brentuximab vedotin

Mesh：

Substances：

Year:  2015        PMID： 26109475     DOI： 10.1002/pbc.25621

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


  5 in total

1.  Lymphoma Secondary to Congenital and Acquired Immunodeficiency Syndromes at a Turkish Pediatric Oncology Center.

Authors:  Hikmet G Tanyildiz; Handan Dincaslan; Gulsan Yavuz; Emel Unal; Aydan Ikinciogulları; Figen Dogu; Nurdan Tacyildiz
Journal:  J Clin Immunol       Date:  2016-08-04       Impact factor: 8.317

2.  Safety and efficacy of brentuximab vedotin as a treatment for lymphoproliferative disorders in primary immunodeficiencies.

Authors:  Thomas Pincez; Julie Bruneau; Laureline Berteloot; Eve Piekarski; Caroline Thomas; Ambroise Marçais; Amélie Trinquand; Martin Castelle; Nicolas Garcelon; Dominique Plantaz; Morgane Cheminant; Despina Moshous; Thierry Jo Molina; Olivier Hermine; Elizabeth Macintyre; Alain Fischer; Stéphane Blanche; Felipe Suarez; Bénédicte Neven
Journal:  Haematologica       Date:  2019-12-26       Impact factor: 9.941

3.  The natural history of ataxia-telangiectasia (A-T): A systematic review.

Authors:  Emily Petley; Alexander Yule; Shaun Alexander; Shalini Ojha; William P Whitehouse
Journal:  PLoS One       Date:  2022-03-15       Impact factor: 3.752

Review 4.  Consensus Recommendations for the Clinical Management of Hematological Malignancies in Patients with DNA Double Stranded Break Disorders.

Authors:  Agata Pastorczak; Andishe Attarbaschi; Simon Bomken; Arndt Borkhardt; Jutte van der Werff Ten Bosch; Sarah Elitzur; Andrew R Gennery; Eva Hlavackova; Arpád Kerekes; Zdenka Křenová; Wojciech Mlynarski; Tomasz Szczepanski; Tessa Wassenberg; Jan Loeffen
Journal:  Cancers (Basel)       Date:  2022-04-14       Impact factor: 6.575

5.  A Systematic Review on Predisposition to Lymphoid (B and T cell) Neoplasias in Patients With Primary Immunodeficiencies and Immune Dysregulatory Disorders (Inborn Errors of Immunity).

Authors:  Irbaz Bin Riaz; Warda Faridi; Mrinal M Patnaik; Roshini S Abraham
Journal:  Front Immunol       Date:  2019-04-16       Impact factor: 7.561
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.